Lesson
Follow HBV From Entry to Liver Injury
HBV persists in hepatocytes through covalently closed circular DNA. Most liver injury reflects the host immune response rather than direct viral cytotoxicity.
- Partially double-stranded DNA
- cccDNA
- Immune injury
- Chronicity
- HCC
virus natural history
Connect viral replication, immune injury, fibrosis, treatment, prevention, and long-term surveillance.
Map replication
HBV enters hepatocytes, converts relaxed circular DNA into nuclear cccDNA, transcribes viral RNA, and uses reverse transcription to produce new viral DNA. Current polymerase inhibitors suppress replication but rarely eliminate cccDNA.
Map injury
Cytotoxic immune responses against infected hepatocytes drive inflammation and fibrosis. ALT reflects injury but can fluctuate and cannot stage disease by itself.
Map chronicity
The probability of chronic infection is highest after perinatal acquisition and falls with later acquisition. Immune suppression can permit reactivation after apparent control.
Map consequences
Persistent inflammation and integration-related biology can lead to cirrhosis, decompensation, and hepatocellular carcinoma. Cancer risk can persist despite viral suppression or HBsAg loss in selected patients.
Quick check
Lesson
Read the Entire Serologic Pattern
CDC now recommends one-time screening of every adult with HBsAg, anti-HBs, and total anti-HBc. This replaces the older RxPrep statement that routine healthy-adult screening is unnecessary.
- HBsAg
- Anti-HBs
- Total anti-HBc
- IgM anti-HBc
- HBV DNA
screening serology
Connect viral replication, immune injury, fibrosis, treatment, prevention, and long-term surveillance.
Use the triple panel
HBsAg indicates current infection, anti-HBs usually indicates immunity, and total anti-HBc indicates current or prior natural infection. Vaccine immunity produces anti-HBs without anti-HBc.
Separate acute from chronic
IgM anti-HBc supports recent acute infection but may also appear during severe chronic flares. HBsAg persisting at least six months supports chronic infection.
Resolve isolated core antibody
Isolated total anti-HBc may reflect remote resolved infection with waned anti-HBs, false positivity, window-period infection, or occult HBV. Use exposure, immune status, repeat testing, and HBV DNA as needed.
Complete the baseline
For HBsAg-positive patients, assess HBV DNA, HBeAg and anti-HBe, ALT and other liver tests, fibrosis, HIV, HCV, HDV context, pregnancy, family history, medications, alcohol, metabolic disease, and HCC risk.
Quick check
Lesson
Stage a Dynamic Disease
HBeAg, HBV DNA, ALT, and fibrosis interact over time. No single result defines the whole phase or treatment need.
- HBeAg
- HBV DNA
- ALT
- Fibrosis
- Cirrhosis
phase staging
Connect viral replication, immune injury, fibrosis, treatment, prevention, and long-term surveillance.
Trend viral activity
Interpret HBV DNA and HBeAg over time. HBeAg-negative disease can remain highly replicative because precore or basal-core-promoter variants do not require HBeAg production.
Trend inflammation
Use serial ALT and clinical context. A normal value does not exclude significant fibrosis, and elevation requires evaluation for HBV activity and competing liver injury.
Stage fibrosis
Use validated noninvasive scores, elastography, imaging, laboratory evidence, and biopsy when needed. Cirrhosis changes treatment thresholds and surveillance.
Name the phase carefully
Current guidance recognizes immune-active, inactive, immune-tolerant, and indeterminate patterns. Age, fibrosis, family history, comorbidity, coinfection, and transmission risk can alter action within a phase.
Quick check
Lesson
Treat Risk, Not One Threshold
The 2025 AASLD and 2024 WHO frameworks expanded and clarified treatment decisions beyond the compact 2023 textbook table.
- Cirrhosis
- Immune active
- Indeterminate
- Transmission
- Shared decision
treatment decision
Connect viral replication, immune injury, fibrosis, treatment, prevention, and long-term surveillance.
Treat advanced disease
Cirrhosis with detectable HBV DNA and significant fibrosis generally favor therapy even when ALT is not elevated. Decompensation requires specialist treatment and transplant-aware care.
Treat immune-active disease
HBV DNA, ALT, inflammation, and fibrosis support treatment. Exact thresholds and special populations differ across AASLD and WHO settings.
Handle indeterminate disease
Current AASLD guidance emphasizes age, fibrosis, inflammation, family history, comorbidity, and shared decision-making rather than passive indefinite observation.
Use prevention indications
Pregnancy with high HBV DNA, HIV coinfection, immunosuppression, household or horizontal transmission risk, and selected pediatric contexts can create treatment or prophylaxis indications.
Quick check
Lesson
Choose a High-Barrier Polymerase Inhibitor
TDF, TAF, and entecavir are central oral options. Their shared antiviral goal does not make their renal, bone, food, liver, resistance, or coinfection profiles interchangeable.
- TDF
- TAF
- Entecavir
- Polymerase
- Resistance barrier
polymerase therapy
Connect viral replication, immune injury, fibrosis, treatment, prevention, and long-term surveillance.
Use TDF deliberately
TDF 300 mg daily is potent and high barrier, but requires renal dose adjustment and surveillance for proximal tubular injury, kidney decline, and bone effects.
Use TAF within its label
Vemlidy 25 mg daily with food has lower plasma tenofovir exposure and generally less renal and bone toxicity. Current U.S. labeling covers compensated liver disease and defined pediatric age and weight criteria.
Use entecavir correctly
Nucleoside-naive adults generally receive 0.5 mg daily on an empty stomach. Lamivudine resistance or decompensated disease uses a different 1 mg context, and kidney impairment requires adjustment.
Avoid low-barrier shortcuts
Lamivudine, adefovir, and telbivudine have resistance or toxicity disadvantages. Prior exposure and resistance must shape salvage therapy.
Quick check
Lesson
Use Immune Therapy Only for a Selected Patient
Peginterferon can offer finite therapy without polymerase resistance, but response is limited and toxicity is substantial.
- Pegylation
- Finite course
- Immune modulation
- Depression
- Decompensation
peginterferon selection
Connect viral replication, immune injury, fibrosis, treatment, prevention, and long-term surveillance.
Explain the mechanism
Peginterferon enhances antiviral immune activity and has antiproliferative effects. Pegylation prolongs exposure and enables weekly administration.
Select the phenotype
A compensated patient with favorable viral and host predictors, reliable monitoring, and a strong preference for finite therapy may be considered under current specialist guidance.
Screen exclusions
Decompensated cirrhosis, severe uncontrolled psychiatric disease, major autoimmune disease, cytopenias, uncontrolled thyroid disease, pregnancy, and other product-specific risks can exclude treatment.
Monitor the whole patient
Track blood counts, liver tests, thyroid, mood, infection, autoimmune symptoms, vision, glucose, and virologic response. Flu-like symptoms do not represent the full safety burden.
Quick check
Lesson
Adapt Therapy to Organ and Viral Context
Kidney disease, bone disease, HIV, HCV, HDV, prior resistance, and decompensated liver disease can change both drug and monitoring.
- Renal function
- Bone health
- HIV
- HDV
- HCV
special populations
Connect viral replication, immune injury, fibrosis, treatment, prevention, and long-term surveillance.
Protect kidney and bone
Review eGFR or creatinine clearance, phosphorus and urine markers when indicated, dialysis, fractures, osteoporosis, steroids, and nephrotoxins before choosing and during therapy.
Protect HIV treatment
Test for HIV before HBV monotherapy. Coinfection generally requires a fully suppressive HIV regimen with tenofovir plus emtricitabine or lamivudine as dual HBV-active coverage.
Find viral coinfection
Use current guidance for HDV testing in HBsAg-positive patients. Before HCV direct-acting antivirals, define HBV status and create prophylaxis or monitoring for reactivation risk.
Escalate decompensation
Avoid peginterferon, use a potent oral agent appropriate to organ function, monitor closely, and coordinate transplant-capable hepatology care.
Quick check
Lesson
Break Perinatal Transmission
Maternal viral suppression and newborn immunoprophylaxis are complementary, not competing strategies.
- HBV DNA
- TDF
- TAF
- Vaccine
- HBIG
pregnancy infant
Connect viral replication, immune injury, fibrosis, treatment, prevention, and long-term surveillance.
Screen every pregnancy
Test HBsAg during each pregnancy and obtain HBV DNA for an HBsAg-positive patient. Link the parent to liver care and the perinatal prevention program.
Use maternal prophylaxis when indicated
Current AASLD guidance supports TDF or selected TAF beginning around week 28 for high viral load under specialist care. WHO guidance also expands prophylaxis eligibility in some settings.
Protect the newborn immediately
An infant born to an HBsAg-positive parent needs vaccine and HBIG within 12 hours. Unknown status requires urgent vaccine and status-directed HBIG action.
Prove protection
Complete the vaccine series and obtain post-vaccination serologic testing at the recommended age. Document the result and revaccination or infection pathway if protection failed.
Quick check
Lesson
Suppress Replication Without Losing the Follow-up
HBV therapy is often long term. Adherence, response, safety, and surveillance remain active even when DNA becomes undetectable.
- HBV DNA
- ALT
- Adherence
- Renal safety
- Post-treatment flare
monitoring stopping
Connect viral replication, immune injury, fibrosis, treatment, prevention, and long-term surveillance.
Monitor effectiveness
Trend HBV DNA and ALT, evaluate serologic transitions when relevant, and reassess fibrosis and clinical status. Persistent viremia first demands an adherence and interaction audit.
Monitor safety
Track kidney and bone parameters for tenofovir according to agent and risk, and use broader product-specific monitoring for peginterferon.
Prevent treatment gaps
Refill access, insurance, travel, transitions, hospitalization, and antiretroviral changes can interrupt HBV-active therapy. Treat continuity as a safety requirement.
Stop only through a guideline pathway
Current AASLD guidance is restrictive about discontinuation and emphasizes HBsAg loss. Any stop requires exclusion of cirrhosis, explicit relapse criteria, and close laboratory and clinical monitoring for severe flare.
Quick check
Lesson
Prevent HBV Reactivation Before Immunosuppression
B-cell depletion and other potent immunosuppression can reactivate chronic or resolved HBV, sometimes after therapy ends.
- HBsAg
- Anti-HBc
- B-cell depletion
- Prophylaxis
- Monitoring
reactivation
Connect viral replication, immune injury, fibrosis, treatment, prevention, and long-term surveillance.
Screen with the triple panel
HBsAg alone misses patients with resolved infection who remain anti-HBc positive. Complete serology allows risk classification.
Rank regimen risk
Anti-CD20 therapy, stem-cell transplantation, many cancer regimens, solid-organ transplantation, high-dose corticosteroids, and selected targeted agents create different reactivation risks.
Choose prophylaxis or monitoring
HBsAg-positive patients and high-risk anti-HBc-positive patients commonly need prophylaxis with a high-barrier agent. Lower-risk contexts may use frequent ALT, HBsAg, and HBV DNA monitoring when follow-up is reliable.
Continue beyond immunosuppression
Reactivation can be delayed. Duration after therapy depends on immune regimen, HBV status, antiviral, and current specialty guidance.
Quick check
Lesson
Prevent Infection and Detect Cancer Early
Vaccination, contact protection, safer exposure practices, and HCC surveillance extend care beyond the prescription.
- Vaccination
- Household contacts
- Birth dose
- Ultrasound
- AFP
prevention surveillance
Connect viral replication, immune injury, fibrosis, treatment, prevention, and long-term surveillance.
Vaccinate susceptible people
CDC recommends HepB vaccination for adults age 19 through 59 and older adults with risk factors or who request protection. Vaccinate susceptible household and sexual contacts.
Use the current infant schedule
December 2025 CDC guidance retained vaccine within 12 hours for infants of HBsAg-positive or unknown-status parents and moved confirmed-negative-parent birth timing to shared clinical decision-making.
Reduce exposure
Cover wounds, do not share needles or blood-contaminated personal items, use safer sex and injection practices, and clean blood spills appropriately. HBV is not spread through ordinary casual contact.
Continue HCC surveillance
Current AASLD criteria use cirrhosis and demographic, family, ancestry, and coinfection risk. When indicated, ultrasound with AFP about every six months remains standard even during suppression.
Quick check
Lesson
Close the Chronic HBV Loop
Complete care links screening, serology, staging, treatment, prevention, monitoring, surveillance, and every life transition.
- Screen
- Stage
- Treat
- Prevent
- Own
integrated case
Connect viral replication, immune injury, fibrosis, treatment, prevention, and long-term surveillance.
Define infection and phase
Document the full triple panel, chronicity, HBV DNA, HBeAg status, ALT trend, fibrosis, cirrhosis, symptoms, coinfections, pregnancy, family history, and HCC risk.
Engineer treatment
State the current guideline indication, exact drug and dose, organ adjustment, food rule, resistance history, interaction review, adherence plan, and alternative.
Engineer prevention
Vaccinate susceptible contacts, address blood and sexual exposure, plan pregnancy and newborn prophylaxis, and protect against immunosuppression-related reactivation.
Engineer continuity
Schedule virologic and safety labs, fibrosis reassessment, HCC surveillance, refill continuity, transfer communication, and urgent actions for interruption, flare, or decompensation.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 100 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.